IP Library › Patent Application 10538066
Patent Application
App. No. 10/538,066

Hla-a1,-a2,-a3,-a24,-b7, and-b44 tumor associated antigen peptides and compositions

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
10/538,066
Abstract

A peptide or composition comprising at least one epitope or analog from CEA, HER2/neu, MAGE2, MAGE3, or p53.

Claims (21)

1 - 31 . (canceled)

32 . An isolated peptide less than about 50 amino acids in length, wherein said peptide comprises an epitope or analog derived from a tumor associated antigen, and wherein said antigen is selected from the group consisting of: carcinoembryonic antigen (CEA), p53, HER2/neu, MAGE 2 and MAGE 3.

33 . A composition comprising the peptide of claim 32 and a carrier.

34 . The composition of claim 33 , further comprising a CTL-inducing peptide.

35 . The composition of claim 34 , wherein said CTL-inducing peptide also comprises an epitope or analog derived from a tumor associated antigen selected from the group set out in claim 32 .

36 . The composition of claim 33 , further comprising a T helper peptide.

37 . The composition of claim 36 , wherein said T helper peptide is a pan-DR binding epitope.

38 . A composition comprising at least three peptides, wherein each of said peptides comprises an epitope or analog derived from a tumor associated antigen selected from the group set out in claim 32 .

39 . The composition of claim 33 , further comprising a liposome, wherein said peptide is on or within said liposome.

40 . The composition of claim 33 , further comprising a lipid.

41 . The composition of claim 33 , wherein said peptide is linked to a spacer molecule.

42 . The composition of claim 33 , further comprising an antigen presenting cell, wherein said peptide is on or within said antigen presenting cell.

43 . The composition of claim 42 , wherein said antigen presenting cell is a dendritic cell.

44 . A polypeptide comprising at least a first epitope and a second epitope, wherein said first epitope comprises an epitope or analog derived from a tumor associated antigen selected from the group set out in claim 32 .

45 . A composition comprising the polypeptide of claim 44 , wherein each of said first epitope and said second epitope comprises an epitope or analog derived from a tumor associated antigen selected from the group set out in claim 32 .

46 . A composition comprising the polypeptide of claim 44 , wherein said polypeptide is a homopolymer.

47 . A composition comprising the polypeptide of claim 44 , wherein said polypeptide is a heteropolymer.

48 . An isolated nucleic acid encoding the peptide of claim 32 .

49 . An isolated nucleic acid encoding the polypeptide of claim 44 .

50 . A method of treating or preventing cancer in a mammal comprising administering the peptide of claim 32 to a mammal in need thereof.

51 . A method of treating or preventing cancer in a mammal comprising administering the nucleic acid of claim 48 to a mammal in need thereof.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 31, 2014
From: IDM PHARMA, INC.
To: BIOTECH SYNERGY, INC.
Reel/Frame 033453/0170 →